An article published in the Journal of Clinical Oncology finds that survivorship care plans may not greatly improve patient satisfaction with their care.
With earlier diagnosis and improved treatment options, cancer survivorship is more common place today than a decade ago. However, long-term survivors have to grapple with physical and mental health issues associated with their cancer treatment. To understand the impact of survivorship care plans (SCPs) on patient satisfaction with information and the care received, researchers evaluated endometrial cancer patients and studied the impact of automatically generated SCPs on the above primary outcomes. Secondary outcomes were illness perceptions and healthcare use.
Newly diagnosed endometrial cancer patients filled out questionnaires immediately following diagnosis, after diagnosis, and 6 and 12 months following diagnosis. Of the nearly three-quarter patients who received an SCP in the SCP care arm, the reported increased information on available care and sites of care did not improve patient satisfaction with information or with care, compared with the control arm. These patients also reported more symptoms, were more concerned and emotionally affected by their illness. An important aspect of this SCP was the inclusion of the patient's primary care physician (PCP) in the plan, which is important when it comes to integrated care of cancer patients. However, the increased contact with their PCP during cancer treatment did not greatly influence patient satisfaction with care.
While evidence exists on SCPs being used, not much is known about the impact of SCPs on patient satisfaction. The current results have added to the vacuum that exists around this information. Importantly, they override the presumption that care plans improve outcomes and patient satisfaction. It is unclear though whether these effects are harmful or beneficial for patients. “One could argue that receiving an SCP raises patients’ awareness of cancer-related symptoms and empowers them to find the necessary support,” even if they don’t recognize this as a benefit, the investigators write.
The emotional stress that patients expressed about their illness calls for intervention on the psychological impact that a life-threatening disease like cancer can have on patients and their families. The data can also help physicians make informed decisions on larger-scale implementation of SCPs.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More